par2 activating matriptase (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
95
Structured Review
R&D Systems
par2 activating matriptase
Par2 Activating Matriptase, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 30 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/matriptase/Recombinant+Human+Matriptase%2FST14+Catalytic+Domain%2C+CF/pmc13098787-140-26-30
Average 95 stars, based on 30 article reviews
Par2 Activating Matriptase, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 30 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/matriptase/Recombinant+Human+Matriptase%2FST14+Catalytic+Domain%2C+CF/pmc13098787-140-26-30
Average 95 stars, based on 30 article reviews
par2 activating matriptase - by Bioz Stars,
2026-11
95/100 stars
Images
1) Product Images from "Monoclonal antibody inhibition of PAR2 reduces phenotype severity and pain in murine inflammatory bowel disease"
Article Title: Monoclonal antibody inhibition of PAR2 reduces phenotype severity and pain in murine inflammatory bowel disease
Journal: Pain Reports
doi: 10.1097/PR9.0000000000001446
Figure Legend Snippet: Colonic PAR2 activation by 2F elicits LSN responses that are mediated by endosomal internalization, PKA and PKC. (A) Experimental framework for LSN recordings showing a cannulated colon in a recording chamber with the LSN aspirated into a suction electrode. (B) Representative action potentials recorded from LSN afferent fiber prestimulation. (C and D) 100 µM 2F application elicits LSN responses illustrated by (C) action potential traces prestimulation and 15 minutes poststimulation and (D) change in LSN firing rate over time after stimulation via the luminal inflow (vertical dotted line). 2F-stimulation increased LSN firing (E and F). Timeline and peak change in firing rate after 100 µM 2F application (vertical dotted line) in tissue pretreated with (E) 50 µM PitStop2 (PS2) inhibitor for endosomal internalization or negative control PitNot2 (PN2) and (F) 100 µM H-89 dihydrochloride (H-89) and bisindolylmaleimide (GFX), PKA and PKC inhibitors or DMSO vehicle. (E) PS2 as well as separate and simultaneous pretreatment with H-89 and GFX reduced the peak response to 2F. (D and E) Independent samples t test comparing the peak change in firing rate (N = 5–9). (F) One-way ANOVA with post-hoc FDR-corrected independent samples t test (N = 5–6). * P < 0.05, ** P < 0.01, *** P < 0.001 **** P < 0.0001. Data are presented as mean ± SD. LSN, lumbar splanchnic nerve; PAR2, protease-activated receptor 2; PKA, protein kinase A; PKC, protein kinase C.
Techniques Used: Activation Assay, Negative Control
Figure Legend Snippet: PAR2 activation in the colon by 2F sensitizes LSN responses to mechanical and chemical stimulation of the colon via endosomal internalization, PKA and PKC. LSN action potential firing after mechanical distention: gradually increasing intraluminal pressure from 0 to 80 mm Hg, and chemical application: 1 mM cinnamaldehyde and 1 µM capsaicin are illustrated in (A). (B) Responses to distention were quantified through the change in firing rate over increasing discrete pressure values. (C and D) Responses to chemical stimuli were quantified through the change in firing rate over time after application (vertical dotted line). 100 µM 2F stimulation, but not vehicle control, elicited sensitization of the LSN to (B) distention, (C) cinnamaldehyde, and (D) capsaicin. Pretreatment with PS2 before 2F stimulation reduced subsequent LSN responses to distention, cinnamaldehyde, and capsaicin compared with PN2. Pretreatment with H-89 and GFX, applied either simultaneously or individually, also reduced subsequent peak LSN responses to distention, cinnamaldehyde, and capsaicin compared with DMSO vehicle. (B–D) Independent samples t tests and one-way ANOVA with post-hoc FDR-corrected independent samples t test (N = 5–9). * P < 0.05, ** P < 0.01, **** P < 0.0001. Data are presented as means ± SD. LSN, lumbar splanchnic nerve; PAR2, protease-activated receptor 2; PKA, protein kinase A; PKC, protein kinase C.
Techniques Used: Activation Assay, Control
Related Articles
Concentration Assay:Article Title: Macrocyclic inhibitors of HGF-activating serine proteases overcome resistance to receptor tyrosine kinase inhibitors and block lung cancer progression Article Snippet: .. Fluorescent Kinetic Enzyme Inhibitor Assays of HGFA, Article Title: Mechanism-Based Macrocyclic Inhibitors of Serine Proteases. Article Snippet: Protease inhibitor drug discovery is challenged by the lack of cellular and oral permeability, selectivity, metabolic stability, and rapid clearance of peptides.. Here, we describe the rational design, synthesis, and evaluation of peptidomimetic side-chain-cyclized macrocycles which we converted into covalent serine protease inhibitors with the addition of an electrophilic ketone warhead.. We have identified potent and selective inhibitors of TMPRSS2, matriptase, hepsin, and HGFA and demonstrated their improved protease selectivity, metabolic stability, and pharmacokinetic (PK) properties. Recombinant:Article Title: Macrocyclic inhibitors of HGF-activating serine proteases overcome resistance to receptor tyrosine kinase inhibitors and block lung cancer progression Article Snippet: .. Fluorescent Kinetic Enzyme Inhibitor Assays of HGFA, Article Title: Mechanism-Based Macrocyclic Inhibitors of Serine Proteases. Article Snippet: Protease inhibitor drug discovery is challenged by the lack of cellular and oral permeability, selectivity, metabolic stability, and rapid clearance of peptides.. Here, we describe the rational design, synthesis, and evaluation of peptidomimetic side-chain-cyclized macrocycles which we converted into covalent serine protease inhibitors with the addition of an electrophilic ketone warhead.. We have identified potent and selective inhibitors of TMPRSS2, matriptase, hepsin, and HGFA and demonstrated their improved protease selectivity, metabolic stability, and pharmacokinetic (PK) properties. Activation Assay:Article Title: Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate Article Snippet: .. For protease activation, anti-CD71 PDC was diluted to 1 mg/mL in PBS and incubated with 10% volume of Incubation:Article Title: Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate Article Snippet: .. For protease activation, anti-CD71 PDC was diluted to 1 mg/mL in PBS and incubated with 10% volume of other:Article Title: Macrocyclic inhibitors of HGF-activating serine proteases overcome resistance to receptor tyrosine kinase inhibitors and block lung cancer progression Article Snippet: Using GraphPad Prism version 6.04 software program, (GraphPad Software, San Diego, CA, www.graphpad.com ), a four parameter curve fit was used to determine the inhibitor IC 50 s from a plot of the mean reaction velocity versus the inhibitor concentration. . Statistical Analysis: Data analysis was performed using Prism software (version 6.04: Graphpad, La Jolla, CA, USA). p-values of less than 0.05 were considered statistically significant. |
